Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetMAb plus bevacizumab and paclitaxel versus placebo plus bevacizumab and paclitaxel in metastatic triple-negative breast cancer
2010-020101-32Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) and breast cancer comparing MetMAb + bevacizumab + paclitaxel with Placebo + bevacizumab + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2010; status: completed.
02
Drugs
onartuzumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2010-020101-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020101-32.